2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Lymphoma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Interventions
Imatinib Mesylate
142
nilotinib
94
Cyclophosphamide
91
fludarabine phosphate
75
fludarabine
67
Dasatinib
63
Mycophenolic Acid
60
Whole-Body Irradiation
59
Tacrolimus
47
Busulfan
45
Cyclosporine
36
Peripheral Blood Stem Cell Transplantation
35
Cytarabine
35
Melphalan
30
bosutinib
27
ponatinib
26
Granulocyte Colony-Stimulating Factor
26
thymoglobulin
25
Thiotepa
25
Methotrexate
25
Filgrastim
25
asciminib
24
Antilymphocyte Serum
24
Stem Cell Transplantation
22
Sirolimus
17
Interferon-alpha
16
sargramostim
15
Cord Blood Stem Cell Transplantation
14
Clofarabine
13
Bone Marrow Transplantation
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Immunotherapy, Active
×
Clear all
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled